VALENCIA, Spain, Oct. 24, 2023 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will participate in the Spanish Meeting on Oligonucleotide Therapeutics (SMOT III), taking place October 26-27, 2023, at the Faculty of Pharmacy of the University of Valencia. SMOT III is supported by the Conselleria D’Innovació, Universitats, Ciencies i Societat Digital of the Generalitat Valenciana, the Oligonucleotide Therapeutics Society (OTS), and its sponsoring companies, including ARTHEx.
SMOT III is a cutting-edge event that brings together experts, researchers, entrepreneurs, investors, and companies in the field of therapeutic oligonucleotides to promote collaboration, knowledge exchange, and the latest advances in this exciting field.
ARTHEx and the biomedical research center of Hospital La Fe (IIS La Fe), are organizing the event. In addition, ARTHEx’s CSO and co-founder, Beatriz Llamusi, is one of the welcome/closing speakers to the event and will be Chairwoman of certain meeting sessions.
Details of the ARTHEx presentations during SMOT III are below:
Date/Time: Thursday, October 26, 2023, 9:30h – 11:00h CET
Presenter: Beatriz Llamusi, CSO and co-founder of ARTHEx Biotech
Session Title: Successful stories: Oligonucleotide therapeutics entrepreneurship projects
Title: “How to turn a therapeutic project into a clinical stage company”
Date/Time: Friday, October 27, 2023, 14:00h – 16:00h CET
Presenter: Nuria Barquero, Head of Toxicology of ARTHEx Biotech
Session Title: Preclinical tools and development
Title: “Preclinical development of antimiR ATX-01”
More information about SMOT III, including registration details and the program, is located here: link.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company’s lead investigational compound, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters is in Valencia, Spain.
For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
Company Contact
Frédéric Legros
Executive Chairman and CEO
[email protected]
+33679495790
Investor and Media Contact
Amy Conrad
Juniper Point
[email protected]
+1 858-366-3243
SOURCE ARTHEx Biotech
